Lyssavirus Vaccine with a Chimeric Glycoprotein Protects across Phylogroups

Christine R. Fisher; David E. Lowe; Todd G. Smith; Yong Yang; Christina L. Hutson; Christoph Wirblich; Gino Cingolani; Matthias J. Schnell

doi:10.1016/j.celrep.2020.107920

Publisher Website

Lyssavirus Vaccine with a Chimeric Glycoprotein Protects across Phylogroups

Authors

Fisher, Christine R.¹
Lowe, David E.²
Smith, Todd G.²
Yang, Yong²
Hutson, Christina L.²
Wirblich, Christoph¹
Cingolani, Gino³
Schnell, Matthias J.^{1, 4}

¹ Department of Microbiology and Immunology, Thomas Jefferson University, Philadelphia, PA 19107, USA
² National Center for Emerging and Zoonotic Infectious Diseases, Division of High-Consequence Pathogens and Pathology, Poxvirus and Rabies Branch, Centers for Disease Control and Prevention (CDC), Atlanta, GA 30333, USA
³ Department of Biochemistry and Molecular Biology, Thomas Jefferson University, Philadelphia, PA 19107, USA
⁴ Jefferson Vaccine Center, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA 19107, USA

Type

Published Article

Journal

Cell Reports

Publisher

Elsevier

Publication Date

Jul 21, 2020

Volume

32

Issue

3

Pages

107920–107920

Identifiers

DOI: 10.1016/j.celrep.2020.107920

PMID: 32697993

PMCID: PMC7373069

Source

PubMed Central

Keywords

License

Unknown

Abstract

Rabies-related viruses cause a similar disease as rabies virus, but protection is not always induced by current vaccines. Fisher et al. design a vaccine featuring a functional, chimeric envelope protein that combines parts of two highly divergent viruses. The vaccine generates robust immune responses and protects against disease in mice.

Report this publication

Statistics

Seen <100 times